Although T cell responses to the quantitatively major myelin proteins, myelin basic protein (MBP) and proteolipid protein (PLP), are likely to be of importance in the course of multiple sclerosis (MS), cell-mediated autoimmune responses to other myelin antigens, in particular quantitatively minor myelin antigens, such as myelin-associated glycoprotein (MAG) and the central nervous system-specific myelin oligodendrocyte glycoprotein (MOG), could also play a prevalent role in disease initiation or progression. Highly purified myelin antigens were used in this study to assess cell-mediated immune response to MOG in MS patients, in the context of the reactivity to other myelin antigens, MBP, PLP, and MAG. The greatest incidence of proliferative response by MS peripheral blood lymphocytes was to MOG, as 12 of 24 patients tested reacted and, of these 
Introduction
Multiple sclerosis (MS),' a disease of the human central nervous system (CNS) characterized by perivascular inflammation accompanied by primary demyelination, is believed to result from autoimmune mechanisms leading to myelin destruction (1) . Accumulation of activated T cells in early MS lesions, as well as at the periplaque area and in surrounding normal-appearing white matter (2) (3) (4) , seemingly points to the 1 . Abbreviations used in this paper: CNS, central nervous system; CSF, cerebrospinal fluid; EAE, experimental autoimmune encephalomyelitis; MAG, myelin-associated glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; PLP, proteolipid protein; SI, stimulation index.
importance ofcell-mediated immune reaction in the pathogenesis ofthe disease ( 1, 5) . In view ofthe restricted localization of MS lesions to the white matter (6) , it is generally accepted that autoimmune-activated T cells in MS CNS recognize components of the myelin sheath. In this context, a purported model for MS, experimental autoimmune encephalomyelitis (EAE), was shown to be a cell-mediated disease that could be caused in susceptible animals by intravenous injection of activated CD4' T cells specific for the quantitatively major myelin proteins: myelin basic protein (MBP) (7, 8) and proteolipid protein (PLP) (9-1 1 ). In MS, reactivity to these myelin antigens has been extensively investigated and controversial results indicate that, although specific responses to these antigens are likely to be ofimportance in the course ofthe disease, they may not represent the primordial response involved in the pathogenesis ( 12) . It has recently been acknowledged that autoimmune recognition ofquantitatively minor myelin autoantigens in MS could also play a prevalent role in disease initiation or progression. Quantitatively minor myelin antigens include myelin-associated glycoprotein (MAG) and the CNS-specific myelin ohgodendrocyte glycoprotein (MOG) . In contrast to MBP and PLP, which account for most of the protein fraction of CNS myelin (-30 and 50%, respectively; 13), MAG and MOG constitute only -1 and 0.05% ofCNS myelin proteins, respectively ( 14, 15) . Because oftheir low abundance, it is difficult to obtain these antigens in a highly purified form and in sufficient quantities, hence the paucity ofreports investigating T cell reactivity to MAG and MOG. Although autoimmune response to MAG may be more important in demyelinating disorders of the peripheral nervous system (16) , immune responses to MOG may be highly relevant to CNS demyelination. Thus, despite the fact that only very small amounts of MOG are found in the CNS ( 17) , antibodies to MOG can be detected in the sera of guinea pigs with EAE induced with whole spinal cord homogenate ( 18) . Furthermore, the demyelinating activity of such sera has been attributed to anti-MOG antibodies (19) . Corroborative evidence that the presence of anti-MOG antibodies within CNS tissue leads to extensive demyelination has been obtained both in vivo (20, 21 ) and in vitro (22) with a monoclonal anti-MOG antibody ( 17) . If MOG is indeed a target antigen for autoimmune attack, the possible involvement of cell-mediated immune response to MOG is also likely to be an important factor in the pathogenesis of MS.
In this study, the relevance of MOG as a T cell autoantigen was investigated by assessing the reactivity to MOG by PBLs of MS patients and control individuals, in the context ofthe reactivity to other myelin antigens: MBP, PLP, and MAG. (23) . This highly purified preparation comprises the 18.5-and the 17.3-kD MBP isoforms observed in adult human CNS (Fig. 1 A; 24) .
Human MOG was purified from neurologically normal brain white matter or spinal cord according to the procedure of Webb (personal communication; 17) modified as detailed previously (24a). Briefly, membrane proteins were extracted by addition of deoxycholate to human white matter homogenate and MOG was isolated from the solubilized protein fraction by immunoaffinity chromatography on an anti-MOG IgG (see below) column. It was eluted, in the absence of detergent, with 50 mM diethylamine, pH I11.5, which was then dialyzed out or removed on a desalting column. Human extracellular derivative of MAG (dMAG) was purified as described previously (25) .
PLP was obtained from a washed total lipid extract ofbovine white matter (26) and lipid was removed by chromatography on a Sephadex LH60 column (27) . It was kept as a chloroform/methanol soluble preparation. On the day PLP was to be used in the proliferation assay, an aliquot ofthe solvent-soluble preparation was converted to a watersoluble form and dialyzed extensively against large volumes of water for 10-12 h. All preparations contained the two PLP isoforms, PLP and DM-20.
SDS-PAGE and immunoblotting. SDS-PAGE and immunoblotting analyses of the MOG and MBP preparations were carried out on 15% gels as described previously (24) . SDS-PAGE analyses of MAG and PLP were performed on 10 and 12% gels, respectively (28) . Immunoblotting ofPLP was performed as described by Yamamura et al. (29) with the following modifications: the blocking solution consisted of PBS containing 2% nonfat dry milk and the hybridoma supernatant was used undiluted; the second antibody was goat anti-rat IgG conjugated to alkaline phosphatase (Fisher Scientific Co.), and an alkaline phosphatase conjugate substrate kit (Bio-Rad Laboratories, Richmond, CA) was used for detection.
Antibodies Proliferation assays. PBLs were separated from 20 ml of MS or control blood using Leucosep tubes as described by the manufacturer (Cat. no. ES 030 PP; Esquire Chemie, Switzerland). Isolated PBLs were cultured in microtiter wells in the absence or presence of the relevant antigens (5-25 gg/ml), essentially as described previously (34) . Briefly, 2 X I05 cells/well were incubated in triplicate cultures in RPMI 1640 supplemented with 10 mM Hepes buffer, 2 mM glutamine (Bio-Lab, Jerusalem, Israel), 2-mercaptoethanol (5 X 10-M), antibiotics (penicillin G [100 U/mlJ and streptomycin [100 IO g/ml]), 1 mM sodium pyruvate (Bio-Lab), 1% nonessential amino acids (Bio-Lab), and 10% fresh heat-inactivated autologous plasma. The cultures were incubated at 370C in humidified air containing 7.5% CO2. After determined to be between 5 and 25 gg/ml. In view of the difficulties encountered to purify adequate quantities of MOG suitable for cell culture, the samples were subsequently tested only at two protein concentrations (5 and 25 ztg/ ml) ofthe optimal concentration range; only the highest response observed is given in Results for each patient and control tested. Highest responses to MBP and PLP were generally observed at 5 gg/ml; responses to MOG were generally highest at 25 ,qg/ml.
Statistical analysis. A two-way x2 analysis was performed to compare the association between MS and responsiveness to each myelin antigen tested.
Results
Myelin antigen preparations. Highly purified myelin antigens were used in this study to ensure that reactivity to the various myelin antigens was indeed directed to each antigen being studied and not to small amounts ofother myelin antigens possibly contaminating the preparations. Demonstration of a high degree of homogeneity was particularly important for the MOG preparations as such preparations are easily contaminated with PLP ( 15) , which is present in myelin in considerably greater amounts than MOG (50% as compared with -0.0 1-0.05%).
In addition, such preparations should not contain appreciable levels of MBP, which has so far been shown to be the myelin antigen towards which most of the T cell reactivity is directed ( 12) . As demonstrated by immunoblotting with highly specific antibodies, the MOG preparations were not contaminated with even very low levels of PLP or MBP (Fig. 1 B) . antibody-reactive bands could not be detected in MOG preparations at molecular masses expected for MAG (90-100 kD); however, such reactivity was observed for bands corresponding to MOG (Fig. 1 B) (Fig. 1 B) . Such a procedure yields an undegraded preparation, as indicated by immunoblotting with anti-MBP antibodies (Fig. 1 B) . Coomassie blue staining of a gel lane overloaded with purified human MAG reveals a single band (Fig. 1 A) (Fig. 1 A) . Because (61) .
was unlikely to have a marked effect on the potential T cell reactivity, in view of the very high homology between PLPs from various species (three amino acid differences between bovine and human PLP [ 36 ] ). To ensure that we could indeed detect reactivity to bovine PLP with cells from another species and that conversion of PLP from solvent-soluble form to water-soluble form did not interfere with possible T cell epitopes, the freshly converted PLP preparation was tested on a mouse T cell line specific for a PLP peptide spanning amino acid residues 139-15 1, prepared as detailed previously (7) . As shown in Table I , the water-soluble preparation ofbovine PLP stimulated the PLP-specific mouse T cell line, even when amounts as low as 1 ,ug of the whole protein were used in the assay.
Proliferative responses to the myelin antigens by PBLsfrom MSpatients and control subjects. Levels of reactivity to myelin proteins in standard proliferation assays are notoriously low ( 12, 37) . Low, albeit reproducible, proliferative responses were also observed in the present study. Accordingly, a SI threshold of 2 was arbitrarily selected as representing a positive response. Table II shows the proliferative responses to the various myelin antigens tested by PBLs from MS patients. As can be seen, the greatest incidence of response observed in MS patients was to MOG. Of the 24 MS patients tested, 12 showed a positive response to this antigen, whereas only 5 and 2 responded to MBP and PLP, respectively (Table II) . It is interesting to note that reactivity to MOG was not only more frequent in MS patients than reactivity to MBP and PLP, but the extent of reactivity was also generally higher (see Table II ). In this population of MS patients, only one patient (MS9) responded to MAG; however, the stimulation (SI = 1.92) did not reach our threshold of significance. Although reactivity to MOG of PBLs from MS patients was also seen in combination with reactivity to other myelin antigens, > 66% (8 / 12) of the MS patients responding to MOG reacted to this antigen exclusively (Table II) (Tables   III and IV) .
Statistical analysis of the association between MS and responsiveness to each myelin antigen tested indicated that the association between MS and responsiveness to MOG was highly significant (X2 = 8.37, degree of freedom [d.f.] = 1, p < 0.004; Table IV ). There was no statistically significant association between MS and responsiveness to the other myelin antigens in the MS population tested in this study.
Discussion
In view of the encephalitogenic activity of purified MBP and PLP (reviewed in reference 38) and, more specifically, because MBP-or PLP-specific T cells are sufficient to cause EAE (7) (8) (9) (10) (11) In this study, few MS patients (5 /24; 20.8%) were found to show positive cell-mediated responses to MBP, and a similar proportion (2/ 16; 12.5%) ofcontrol individuals also reacted to this antigen. Although a low frequency of MBP-responsive MS patients was unexpected, in view ofthe data ofsome previously published studies (39) (40) (41) (42) (43) and the assumption that MS is associated with the response to MBP, these results are in line with other studies where PBL sensitization to MBP could be detected in some MS patients, but also in patients with other neurological diseases and in healthy controls ( 37, (44) (45) (46) (47) (48) (49) (50) . Similarly, our data on PLP reactivity, whereby 2 of 24 MS patients reacted positively to this antigen, are in agreement with some studies but in disagreement with others, as diverging results have been obtained by various groups assessing PLP sensitization in MS. Thus, data reported by Trotter et al. (48) showed sensitization to PLP in 6 of 16 patients with chronic progressive MS and 3 of 15 patients with relapsing remitting MS; Sun et al. (51) , using an immunospot assay to detect IFN-y secretion by antigen-specific lymphocytes, reported increased numbers of PLP-reactive T cells in both blood and cerebrospinal fluid MOG has recently attracted a lot of interest in view of its possible role as a target antigen in immune-mediated demyelinating diseases (reviewed in reference 55). Thus, humoral immunity to MOG has been correlated with demyelinating activity in chronic relapsing EAE (18) , and the presence of antibodies to MOG within CNS tissue results in extensive demyelination in vivo (19) (20) (21) and in vitro (22, 56) . In addition to the possible role of anti-MOG antibodies in mediating demyelination, these studies demonstrated the immunogenic potential of MOG, which, despite being present in very low amounts in the CNS ( 15, 17) , can induce important, detectable immune responses in animals injected for EAE with spinal cord or brain homogenates (18, 57) . That MOG may be a primary target for autoimmune responses associated with demyelinating diseases is also strongly suggested by our preliminary results whereby Lewis rats injected with purified human MOG develop a demyelinating and relapsing EAE-like disease with concomitant production ofincreasing levels ofanti-MOG antibody in the serum, to the exclusion of detectable humoral immune response to other myelin proteins (Kerlero de Rosbo, N., T. Johns, K. Menon, S. Abo, and C. Bernard, manuscript in preparation). Because MOG, a highly hydrophobic molecule present in very small quantities in CNS tissue ( 15, 58) , is extremely difficult and cumbersome to purify in quantities and quality required to analyze specific T cell reactivity by standard assays, studies to assess sensitization to this antigen have not been forthcoming. However, in one study, where problems associated with purification ofMOG were circumvented by using the immunospot assay, MOG-reactive T cells were observed in peripheral blood of most of the 14 MS patients studied, whereas only 25% of the 28 controls showed reactivity (59) . Nevertheless, this study is, to the best of our knowledge, the first report of an investigation of the proliferative response to highly purified MOG by PBLs from MS patients. As yet, it is difficult to correlate reactivity to MOG with a particular status of the disease. Neither average duration of the disease (12.08±6.9 and 15.2±6.5 yr for responders and nonresponders, respectively) nor average age of onset (30±11 and 32.5±5.4 yr for responders and nonresponders, respectively) appear to be factors influencing the response to MOG of PBLs from MS patients. Most importantly, the responsiveness to MOG by MS PBLs was not restricted to a particular subgroup of MS patients as it was observed in definite as well as probable MS, in either the relapsing remitting or the chronic-progressive type. Two of the three chronic progressive MS patients (Table  II, MS4 and MS23) responded to MOG, but not to the other three myelin antigens tested, and the two patients with an acute attack (Table II, MS3 and MS22) did not show any reactivity to MOG. However, due to the small number ofpatients in each subgroup, it is difficult to draw any conclusion correlating MOG responsiveness with disease stage. Nevertheless, our study demonstrates not only that assessment ofthe reactivity to minor myelin antigens may be highly relevant to the understanding of MS pathogenesis, but also emphasizes the importance oftesting reactivity to all potential antigens in parallel, in the attempt to assign a primary role to one or the other possible targets. In conclusion, predominance of reactivity to MOG in MS in the context ofcomparatively rarer reactivity to the other myelin antigens tested concomitantly in the same patients shows that MOG may be as important as MBP or PLP in disease pathogenesis and may indeed be the primary target myelin antigen in at least some MS patients. Our observation that MOG itself may also be encephalitogenic (Kerlero de Rosbo, N., T. Johns, K. Menon, S. Abo, and C. Bernard, manuscript in preparation) strongly supports this postulate and emphasizes the relevance of immune responses to MOG in MS. Persistence of MOG reactivity together with reactivity to other myelin antigens could point to a greater role for immune recognition of MOG in disease initiation with broadening of the autoimmune response to additional determinants on this and/ or other autoantigens as the disease progresses. Further studies are in progress to investigate this hypothesis.
